Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 3/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.36 |
| ▸ | USP2 | O75604 | 1/20 | 0.36 |
| ▸ | PPARG | P37231 | 1/20 | 0.36 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.36 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | NR2E3 | Q9Y5X4 | 1/20 | 0.36 |
| ▸ | NCOR2 | Q9Y618 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | CASP1 | P29466 | 1/20 | 0.33 |
| ▸ | CASP7 | P55210 | 1/20 | 0.33 |
| ▸ | GRK6 | P43250 | 1/20 | 0.32 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.31 |
| ▸ | NOS1 | P29475 | 2/20 | 0.30 |
| ▸ | NOS3 | P29474 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8547398 | 0.72 | CYP3A4 (0.36) | MEN1KMT2AUSP2PPARGKEAP1 | |
| SCHEMBL25873873 | 0.67 | MEN1 (0.45) | MEN1KMT2AUSP2PPARGKEAP1 | |
| SCHEMBL5259226 | 0.64 | KMT2A (0.40) | MEN1KMT2AUSP2PPARGKEAP1 | |
| SCHEMBL4364209 | 0.64 | GAA (0.32) | MAPTTRPA1 | |
| SCHEMBL29379681 | 0.64 | GAA (0.32) | MAPTTRPA1 | |
| SCHEMBL25290828 | 0.63 | GAA (0.50) | MAPT | |
| SCHEMBL2210217 | 0.63 | GAA (0.32) | MAPTGRK6 | |
| SCHEMBL330550 | 0.63 | GRK6 (0.34) | MEN1KMT2AUSP2PPARGKEAP1 | |
| SCHEMBL9958738 | 0.63 | GRK6 (0.34) | MEN1KMT2AUSP2PPARGKEAP1 | |
| SCHEMBL2903859 | 0.63 | GRK6 (0.34) | MEN1KMT2AUSP2PPARGKEAP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1234818-B1 | CALCIUM SALTS OF 1,5-BENZODIAZEPINE DERIVATIVES, PROCESS FOR PRODUCING THE SALTS AND DRUGS CONTAINING THE SAME | ZERIA PHARM CO LTD (JP) | 2004-09-08 | — | — | EP | claimed |
| US-6747022-B2 | TREATING DIGESTIVE TRACT DISEASE RESULTING FROM EXCESSIVE SECRETION OF GASTRIC ACID | ZERIA PHARMACEUTICAL CO., LTD. (JP) | 2004-06-08 | — | — | US | claimed |
| US-20030096809-A1 | Calcium salts of 1,5-benzodiazepine derivatives, process for producing the salts and drugs containing the same | ZERIA PHARMACEUTICAL CO., LTD. (JP) | 2003-05-22 | — | — | US | claimed |
| EP-1234818-A1 | CALCIUM SALTS OF 1,5-BENZODIAZEPINE DERIVATIVES, PROCESS FOR PRODUCING THE SALTS AND DRUGS CONTAINING THE SAME | Zeria Pharmaceutical Co., Ltd. (JP) | 2002-08-28 | — | — | EP | claimed |
| EP-2415766-A1 | METHOD FOR MANUFACTURING BENZODIAZEPINE DERIVATIVE | Zeria Pharmaceutical Co., Ltd. (JP) | 2012-02-08 | — | — | EP | disclosed |
| US-20120010401-A1 | METHOD FOR MANUFACTURING 1,5-BENZODIAZEPINE DERIVATIVE | ZERIA PHARMACEUTICAL CO., LTD. (JP) | 2012-01-12 | — | — | US | disclosed |
| EP-1268517-B1 | PROCESS FOR THE PREPARATION OF 3-AMINO-1,5-BENZODIAZEPINE DERIVATIVES | GLAXO GROUP LTD (GB) | 2005-07-06 | — | — | EP | disclosed |
| EP-1234818-B1 | CALCIUM SALTS OF 1,5-BENZODIAZEPINE DERIVATIVES, PROCESS FOR PRODUCING THE SALTS AND DRUGS CONTAINING THE SAME | ZERIA PHARM CO LTD (JP) | 2004-09-08 | — | — | EP | disclosed |
| CN-1161345-C | 1,5-benzodiazepine derivatives as cck-A receptor agonists | — | 2004-08-11 | — | — | CN | disclosed |
| US-6747022-B2 | TREATING DIGESTIVE TRACT DISEASE RESULTING FROM EXCESSIVE SECRETION OF GASTRIC ACID | ZERIA PHARMACEUTICAL CO., LTD. (JP) | 2004-06-08 | — | — | US | disclosed |
| US-6673921-B2 | REDUCTION AND HYDROGENOLYSIS TO FORM A BENZODIAZEPINE | SMITHKLINE BEECHAM CORPORATION | 2004-01-06 | — | — | US | disclosed |
| US-20030158082-A1 | Chemical process | GLAXO WELLCOME INC. | 2003-08-21 | — | — | US | disclosed |
| EP-0785787-B1 | USE OF 1,5-BENZODIAZEPINE DERIVATIVES FOR THE CONTROL OF GASTRIC EMPTYING IN PATIENTS WITH NON-INSULIN DEPENDENT DIABETES MELLITUS | GLAXO WELLCOME INC (US) | 2001-12-12 | — | — | EP | disclosed |
| WO-2001077143-A2 | PROCESS FOR THE PREPARATION OF 3-AMINO-1, 5-BENZODIAZEPINE DERIVATIVES | GLAXO GROUP LIMITED (GB) | 2001-10-18 | — | — | WO | disclosed |
| EP-0694039-B1 | 1,5-BENZODIAZEPINE DERIVATIVES HAVING CCK ANTAGONISTIC AND OR AGONISTIC ACTIVITY | GLAXO WELLCOME INC (US) | 2001-01-24 | — | — | EP | disclosed |
| US-5910495-A | TREATING RAPID GASTRIC EMPTYING IN NON-INSULIN DEPENDENT DIABETIC CONDITIONS; AGONIST ACTIVITY FOR CHOLECYSTOKININ-A RECEPTOR | GLAXO WELLCOME INC. (US) | 1999-06-08 | — | — | US | disclosed |
| US-5780464-A | MODULATORS FOR HORMONES CHOLECYSTOKININ (CCK) AND GASTRIN IN MAMMALS; BIOAVAILABILITY | GLAXO WELLCOME INC. (US) | 1998-07-14 | — | — | US | disclosed |
| US-5646140-A | CHOLECYSTOKININ ANTAGONIST; APETITE CONTROL | GLAXO WELLCOME INC. (US) | 1997-07-08 | — | — | US | disclosed |
| CN-1143362-A | Novel benzodizaepine derivative | SHIONOGI & CO (JP) | 1997-02-19 | — | — | CN | disclosed |
| WO-1994024149-A1 | 1,5-BENZODIAZEPINE DERIVATIVES HAVING CCK ANTAGONISTIC OR AGONISTIC ACTIVITY | GLAXO INC. (US) | 1994-10-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120010401-A1 | METHOD FOR MANUFACTURING 1,5-BENZODIAZEPINE DERIVATIVE | GABRA5, CYP3A5, GABRA1 | MEN1 3263/4885KMT2A 883/4885USP2 3107/4885 |
| US-20030096809-A1 | Calcium salts of 1,5-benzodiazepine derivatives, process for producing the salts and drugs containing the same | CCKBR, CCKAR, GABRB1 | MEN1 2611/4885KMT2A 4022/4885USP2 2975/4885 |
| US-20030158082-A1 | Chemical process | CYP4A11, GRHPR, HSD11B2 | MEN1 727/4885KMT2A 1494/4885USP2 3147/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.